Developer docs
API playgroundTry for free, no card

Search company profiles

MaxWell Biosystems

Full company profile

uuid000278b

Namestring
MaxWell Biosystems
Legal namestring
MaxWell Biosystems AG
Websiteurl
mxwbio.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

MaxWell Biosystems is a Swiss life-sciences tools company founded in 2016 as an ETH Zurich spinoff that develops and commercializes High-Density Microelectrode Array (HD-MEA) platforms for neuroscience research and preclinical drug discovery. Its product portfolio centers on the MaxOne single-well system and the MaxTwo multi-well system (available in 6-, 24-, and 96-well formats), both built on a proprietary CMOS-based switch-matrix chip with 26,400 electrodes that the company describes as the highest electrode count on the market, combined with low-noise recording electronics and the MaxLab Live software for acquisition, spike sorting, and network analysis.

The company monetizes primarily through capital equipment sales of MaxOne and MaxTwo instruments, recurring revenue from proprietary consumables (MaxOne+ Chips and MaxTwo Well Plates), MaxLab Live software licenses, and technical support and training services, with pricing provided via quote rather than publicly disclosed. Go-to-market combines direct enterprise sales supported by global Field Application Scientists with exclusive regional distributors in Japan (Physio-Tech), China (Leads Bio-Technology), Korea (IMsystem), and Poland (I.C.Lab); a wholly-owned US subsidiary, MaxWell Biosystems USA, Inc., was established in San Diego in 2025.

Customers span academic research institutions (e.g., University of Tokyo, UC Santa Barbara, Indiana University, UC Santa Cruz), pharmaceutical and biotech firms (Ricoh Biosciences cited publicly; Roche via the Swiss NGE consortium), CROs, iPSC and organoid cell providers, and an emerging neurocomputing segment, with platform adoption reported in more than 25 countries. Strategic R&D partnerships with Oxford, King's College London, ETH Zurich, MERLN, and the EU-funded HyVIS, MAPSYNE, In-Cytes, Ima-Go, and MO-SAIC consortia, alongside an MRC-Innovate UK £15.9M pain-modeling program, embed MaxWell's technology into major academic and pharma research workflows.

Short descriptiontext

MaxWell Biosystems develops High-Density Microelectrode Array (HD-MEA) platforms for neuroscience research and preclinical drug discovery, serving academic labs, pharmaceutical companies, CROs, and cell providers across 25+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersZurich, Switzerland
HQ citystring
Zurich
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
high-density microelectrode arrays, electrophysiology platforms, neuroscience research instruments, preclinical drug discovery, CMOS bioelectronics
Industry2 codes
PRIMARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHDAHAAAG
Sensors, MEMS & Imaging ICs
NAICS code3 codes
  • Instrument Manufacturing for Measuring and Testing Electricity and Electrical Signals334515
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
  • Semiconductor and Related Device Manufacturing334413
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Instruments For Meas & Testing Of Electricity & Elec Signals3825
Product category
Electrophysiology Instrumentation
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1HD-MEA Hardware Systems
TypeHardware Sales
Description

Sale of MaxOne and MaxTwo HD-MEA platforms including instruments and配套耗材

mxwbio.com
2MEA Chips and Consumables
TypeOne Time License
Description

Recurring revenue from MaxOne+ Chips and MaxTwo Well Plates as consumables

mxwbio.com
3Software Licenses and Support
TypeSubscription Recurring
Description

MaxLab Live software with analytics capabilities for neural data processing

mxwbio.com
4Technical Support and Training
TypeProfessional Services
Description

Expert-level technical and scientific support services, personalized training, and application support

mxwbio.com
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Enterprise/Institutional pricing via direct quote
ModelOtherBilling cadenceMulti-year contract
Notes

No public pricing available - requires contact with sales team for quotes on MaxOne System, MaxTwo System, Chips, and Well Plates

mxwbio.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

MaxWell Biosystems manufactures and sells High-Density Microelectrode Array (HD-MEA) instruments, chips, and software that record and stimulate electrophysiological activity from neurons at single-cell and subcellular resolution. Its flagship products are the MaxOne single-well platform and the MaxTwo multi-well platform, paired with the MaxLab Live software suite, and are used by neuroscience and preclinical drug discovery laboratories worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Strong within-domain performance and above-chance cross-domain generation (ROC-AUC 0.70 ± 0.09 for in vitro → in vivo; 0.80 ± 0.10 for in vivo → in vitro)
+2 more records
Product overview1 text field

MaxWell Biosystems offers a unified HD-MEA platform portfolio comprising MaxOne (single-well) and MaxTwo (multi-well) hardware systems, MaxLab Live software for data acquisition and analysis, and specialized consumable chips and well plates. The MaxOne provides single-well HD-MEA recording for detailed single-cell to network-level analysis, while MaxTwo scales to multi-well formats (6-well, 24-well, 96-well) for higher-throughput applications. Both systems share the proprietary HD-MEA technology with high electrode density and low noise characteristics, and are operated through MaxLab Live software for real-time recording, spike sorting, and network analysis.

Product and service6 records
1MaxOne Single-Well HD-MEA Platform
CategoryHD-MEA Instrument
Description

Single-well High-Density Microelectrode Array platform offering versatility and functionality in one compact device for high-resolution electrophysiological recording from individual cells to neural networks. Designed for academic and pharmaceutical neuroscience research using iPSC-derived neurons, organoids, and brain slices.

2MaxTwo Multi-Well HD-MEA Platform
CategoryHD-MEA Instrument
Description

Multi-well High-Density Microelectrode Array system that maximizes cell functional assays with 6-well, 24-well, and 96-well plate compatibility for higher-throughput electrophysiological screening and assay workflows. Used by pharma, biotech, and CROs for drug discovery and preclinical testing on human iPSC-derived models.

3MaxLab Live Software
CategoryHD-MEA Software
Description

All-in-one software platform for recording, spike sorting, analyzing, and visualizing neuronal activity data from MaxOne and MaxTwo HD-MEA systems, integrated with pipelines such as SpikeInterface, Kilosort, and SpyKING CIRCUS. Licensed to HD-MEA customers.

4MaxOne+ Chip
CategoryHD-MEA Consumable
Description

Advanced consumable chip for the MaxOne system offering enhanced recording capabilities for organoid and neural network studies; sold as a recurring consumable alongside the MaxOne instrument.

5MaxTwo 24-Well Plate
CategoryHD-MEA Consumable
Description

24-well plate consumable for the MaxTwo system enabling higher-throughput electrophysiological screening and assay workflows with single-neuron resolution across multiple wells in parallel.

6MaxTwo 6-Well Plate
CategoryHD-MEA Consumable
Description

6-well plate consumable for the MaxTwo system providing a medium-throughput option for electrophysiological assays with single-neuron resolution.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partner providing optimized human iPSC-derived cells for use with MaxWell HD-MEA platforms

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Service partner providing electrophysiology contract research services using MaxWell technology

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner for extracellular matrix solutions supporting organoid and neuronal culture on HD-MEA platforms

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Lead partner in £15.9M MRC-Innovate UK consortium for Advanced Human In Vitro Models of Pain, using HD-MEA for functional electrophysiological assessment

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner in IUK-Innosuisse project for epilepsy precision medicine, providing patient-specific iPSC brain assembloids

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Founding academic partner and origin of core HD-MEA technology; consortium partner in NGE project for machine-learning assisted electrophysiology platform

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Coordinator of MO-SAIC project for personalized schizophrenia research with midbrain organoids

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Coordinator of EU Horizon 2020 HyVIS project for artificial light-sensitive retinal prosthesis

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner providing ReproPlex iPSC reprogramming technology for epilepsy precision medicine project

Strategic tierMinorTypeStrategic or Co-development Partner
Description

UK consortium partner in MRC-Innovate UK pain research project for drug discovery

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Consortium partner in Swiss NGE project for high-throughput electrophysiological screening platform

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
1MaxWell Biosystems MCS (Multi Channel Systems)
TypeDirect peer
Description

Established German manufacturer of microelectrode array (MEA) systems for electrophysiology, including the MEA2100 and HD-MEA platforms. Directly competes with MaxOne and MaxTwo for neuroscience and cardiac safety screening customers, offering a broader catalog with longer commercial history.

TypeDirect peer
Description

US-based provider of MEA platforms (Maestro) for neuroscience, cardiac, and disease-modeling applications. Closely comparable to MaxWell — both target iPSC-derived neuron screening and pharma high-throughput electrophysiology workflows.

3CytoView (formerly MED64, by Alpha MED Scientific)
TypeDirect peer
Description

Japanese-origin MEA platform provider with multi-well MED64 systems used in academic and pharma electrophysiology. Competes directly in the same HD-MEA/MEA workflow category as MaxWell, particularly across APAC markets.

TypeEmerging player
Description

German electrophysiology instrumentation company specializing in patch-clamp automation (Port-a-Patch, SyncroPatch) and MEA technology. Overlaps with MaxWell's pharma screening use cases but addresses complementary rather than identical workflows.

TypeBroad incumbent
Description

Large-scale life-science instrumentation provider (part of Danaher) offering patch-clamp, MEA, and high-content screening platforms. Addresses similar neuroscience and drug-discovery customers but as part of a much broader portfolio including microplate readers and imaging systems.

TypeEmerging player
Description

US-based neural recording technology company serving BCI and research markets with high-channel-count electrode arrays (NeuroPixels). Comparable technology foundation (high-density CMOS-based neural recording) but different end-application focus — invasive BCI versus in vitro MEA.

TypeEmerging player
Description

Belgian nanoelectronics R&D center developing CMOS-based neural probes and in vitro MEA chips. Overlaps with MaxWell's underlying CMOS-MEA technology approach and serves overlapping neuroscience research customers, though as a research consortium rather than commercial instrument vendor.

TypeEmerging player
Description

Specializes in automated patch-clamp systems (QPatch) for ion channel drug discovery. Adjacent to MaxWell's electrophysiology franchise with overlapping pharma safety-pharmacology customers, but focused on single-cell/manual patch rather than network-level MEA recording.

TypeBroad incumbent
Description

Large analytical instrument manufacturer with presence in neuroscience and cellular analysis. Comparable end customers in pharma and academic neuroscience, but MaxWell's HD-MEA is a niche offering within Bruker's broader microscopy and proteomics portfolio.

TypeOthers
Description

Major CRO offering electrophysiology and safety-pharmacology services, including iPSC-derived neuron screening. Serves as both a potential customer (uses HD-MEA platforms in service offerings) and a competitive threat for outsourced preclinical neuroscience work.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MaxWell Biosystems

Electrophysiology Instrumentationmxwbio.com

MaxWell Biosystems develops High-Density Microelectrode Array (HD-MEA) platforms for neuroscience research and preclinical drug discovery, serving academic labs, pharmaceutical companies, CROs, and cell providers across 25+ countries.

What MaxWell Biosystems does

MaxWell Biosystems is a Swiss life-sciences tools company founded in 2016 as an ETH Zurich spinoff that develops and commercializes High-Density Microelectrode Array (HD-MEA) platforms for neuroscience research and preclinical drug discovery. Its product portfolio centers on the MaxOne single-well system and the MaxTwo multi-well system (available in 6-, 24-, and 96-well formats), both built on a proprietary CMOS-based switch-matrix chip with 26,400 electrodes that the company describes as the highest electrode count on the market, combined with low-noise recording electronics and the MaxLab Live software for acquisition, spike sorting, and network analysis.

The company monetizes primarily through capital equipment sales of MaxOne and MaxTwo instruments, recurring revenue from proprietary consumables (MaxOne+ Chips and MaxTwo Well Plates), MaxLab Live software licenses, and technical support and training services, with pricing provided via quote rather than publicly disclosed. Go-to-market combines direct enterprise sales supported by global Field Application Scientists with exclusive regional distributors in Japan (Physio-Tech), China (Leads Bio-Technology), Korea (IMsystem), and Poland (I.C.Lab); a wholly-owned US subsidiary, MaxWell Biosystems USA, Inc., was established in San Diego in 2025.

Customers span academic research institutions (e.g., University of Tokyo, UC Santa Barbara, Indiana University, UC Santa Cruz), pharmaceutical and biotech firms (Ricoh Biosciences cited publicly; Roche via the Swiss NGE consortium), CROs, iPSC and organoid cell providers, and an emerging neurocomputing segment, with platform adoption reported in more than 25 countries. Strategic R&D partnerships with Oxford, King's College London, ETH Zurich, MERLN, and the EU-funded HyVIS, MAPSYNE, In-Cytes, Ima-Go, and MO-SAIC consortia, alongside an MRC-Innovate UK £15.9M pain-modeling program, embed MaxWell's technology into major academic and pharma research workflows.

MaxWell Biosystems firmographics

Firmographics
Name
MaxWell Biosystems
Legal name
MaxWell Biosystems AG
Website
https://mxwbio.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
MaxWell Biosystems develops High-Density Microelectrode Array (HD-MEA) platforms for neuroscience research and preclinical drug discovery, serving academic labs, pharmaceutical companies, CROs, and cell providers across 25+ countries.
Ownership category
akta.pro rank

MaxWell Biosystems industry classification

Industry
Product category
Electrophysiology Instrumentation
NAICS
Instrument Manufacturing for Measuring and Testing Electricity and Electrical Signals (334515), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Semiconductor and Related Device Manufacturing (334413)
SIC
Laboratory Analytical Instruments (3826), Instruments For Meas & Testing Of Electricity & Elec Signals (3825)
akta.pro industry
PRIMARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHDAHAAAG
Sensors, MEMS & Imaging ICs

Keywords

  • High-density microelectrode arrays
  • Electrophysiology platforms
  • Neuroscience research instruments
  • Preclinical drug discovery
  • CMOS bioelectronics

Where MaxWell Biosystems is headquartered

Location

Headquarters

HQ city
Zurich
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

MaxWell Biosystems business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. HD-MEA Hardware Systems: Sale of MaxOne and MaxTwo HD-MEA platforms including instruments and配套耗材
  2. MEA Chips and Consumables: Recurring revenue from MaxOne+ Chips and MaxTwo Well Plates as consumables
  3. Software Licenses and Support: MaxLab Live software with analytics capabilities for neural data processing
  4. Technical Support and Training: Expert-level technical and scientific support services, personalized training, and application support

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise/Institutional pricing via direct quote

Go-to-market motion3 records

Distribution channels5 records

Marketing channels10 records

MaxWell Biosystems product offering

Product offering

Core offering

MaxWell Biosystems manufactures and sells High-Density Microelectrode Array (HD-MEA) instruments, chips, and software that record and stimulate electrophysiological activity from neurons at single-cell and subcellular resolution. Its flagship products are the MaxOne single-well platform and the MaxTwo multi-well platform, paired with the MaxLab Live software suite, and are used by neuroscience and preclinical drug discovery laboratories worldwide.

Product overview

MaxWell Biosystems offers a unified HD-MEA platform portfolio comprising MaxOne (single-well) and MaxTwo (multi-well) hardware systems, MaxLab Live software for data acquisition and analysis, and specialized consumable chips and well plates. The MaxOne provides single-well HD-MEA recording for detailed single-cell to network-level analysis, while MaxTwo scales to multi-well formats (6-well, 24-well, 96-well) for higher-throughput applications. Both systems share the proprietary HD-MEA technology with high electrode density and low noise characteristics, and are operated through MaxLab Live software for real-time recording, spike sorting, and network analysis.

Differentiator

Problem solved

Functional benefit

Products and services

  • MaxOne Single-Well HD-MEA Platform Single-well High-Density Microelectrode Array platform offering versatility and functionality in one compact device for high-resolution electrophysiological recording from individual cells to neural networks. Designed for academic and pharmaceutical neuroscience research using iPSC-derived neurons, organoids, and brain slices.
  • MaxTwo Multi-Well HD-MEA Platform Multi-well High-Density Microelectrode Array system that maximizes cell functional assays with 6-well, 24-well, and 96-well plate compatibility for higher-throughput electrophysiological screening and assay workflows. Used by pharma, biotech, and CROs for drug discovery and preclinical testing on human iPSC-derived models.
  • MaxLab Live Software All-in-one software platform for recording, spike sorting, analyzing, and visualizing neuronal activity data from MaxOne and MaxTwo HD-MEA systems, integrated with pipelines such as SpikeInterface, Kilosort, and SpyKING CIRCUS. Licensed to HD-MEA customers.
  • MaxOne+ Chip Advanced consumable chip for the MaxOne system offering enhanced recording capabilities for organoid and neural network studies; sold as a recurring consumable alongside the MaxOne instrument.
  • MaxTwo 24-Well Plate 24-well plate consumable for the MaxTwo system enabling higher-throughput electrophysiological screening and assay workflows with single-neuron resolution across multiple wells in parallel.
  • MaxTwo 6-Well Plate 6-well plate consumable for the MaxTwo system providing a medium-throughput option for electrophysiological assays with single-neuron resolution.

Quantifiable outcome

  • Strong within-domain performance and above-chance cross-domain generation (ROC-AUC 0.70 ± 0.09 for in vitro → in vivo; 0.80 ± 0.10 for in vivo → in vitro)
  • +2 more outcomes

Companies that use MaxWell Biosystems

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles3 records

MaxWell Biosystems technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

MaxWell Biosystems partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and minor.

  • bit.biocoreStrategic or Co-development PartnerStrategic partner providing optimized human iPSC-derived cells for use with MaxWell HD-MEA platforms
  • Neuroservice AlliancescoreStrategic or Co-development PartnerService partner providing electrophysiology contract research services using MaxWell technology
  • BioLaminaminorStrategic or Co-development PartnerPartner for extracellular matrix solutions supporting organoid and neuronal culture on HD-MEA platforms
  • University of OxfordcoreStrategic or Co-development PartnerLead partner in £15.9M MRC-Innovate UK consortium for Advanced Human In Vitro Models of Pain, using HD-MEA for functional electrophysiological assessment
  • King's College LondoncoreStrategic or Co-development PartnerPartner in IUK-Innosuisse project for epilepsy precision medicine, providing patient-specific iPSC brain assembloids
  • ETH ZurichcoreStrategic or Co-development PartnerFounding academic partner and origin of core HD-MEA technology; consortium partner in NGE project for machine-learning assisted electrophysiology platform
  • MERLN InstitutecoreStrategic or Co-development PartnerCoordinator of MO-SAIC project for personalized schizophrenia research with midbrain organoids
  • Istituto Italiano di Tecnologia (IIT)minorStrategic or Co-development PartnerCoordinator of EU Horizon 2020 HyVIS project for artificial light-sensitive retinal prosthesis
  • Oxford StemTechcoreStrategic or Co-development PartnerPartner providing ReproPlex iPSC reprogramming technology for epilepsy precision medicine project
  • Medicines Discovery CatapultminorStrategic or Co-development PartnerUK consortium partner in MRC-Innovate UK pain research project for drug discovery
  • F. Hoffmann-La Roche Ltd.coreStrategic or Co-development PartnerConsortium partner in Swiss NGE project for high-throughput electrophysiological screening platform

Scale indicators5 records

Recent moves9 records

Expansion highlights8 records

MaxWell Biosystems competitors and assessment

Company assessment

Direct peers

  • MaxWell Biosystems MCS (Multi Channel Systems): Established German manufacturer of microelectrode array (MEA) systems for electrophysiology, including the MEA2100 and HD-MEA platforms. Directly competes with MaxOne and MaxTwo for neuroscience and cardiac safety screening customers, offering a broader catalog with longer commercial history.
  • Axion Biosystems: US-based provider of MEA platforms (Maestro) for neuroscience, cardiac, and disease-modeling applications. Closely comparable to MaxWell — both target iPSC-derived neuron screening and pharma high-throughput electrophysiology workflows.
  • CytoView (formerly MED64, by Alpha MED Scientific): Japanese-origin MEA platform provider with multi-well MED64 systems used in academic and pharma electrophysiology. Competes directly in the same HD-MEA/MEA workflow category as MaxWell, particularly across APAC markets.

Emerging players

  • Nanion Technologies: German electrophysiology instrumentation company specializing in patch-clamp automation (Port-a-Patch, SyncroPatch) and MEA technology. Overlaps with MaxWell's pharma screening use cases but addresses complementary rather than identical workflows.
  • Blackrock Microsystems: US-based neural recording technology company serving BCI and research markets with high-channel-count electrode arrays (NeuroPixels). Comparable technology foundation (high-density CMOS-based neural recording) but different end-application focus — invasive BCI versus in vitro MEA.
  • Imec: Belgian nanoelectronics R&D center developing CMOS-based neural probes and in vitro MEA chips. Overlaps with MaxWell's underlying CMOS-MEA technology approach and serves overlapping neuroscience research customers, though as a research consortium rather than commercial instrument vendor.
  • Sophion Bioscience: Specializes in automated patch-clamp systems (QPatch) for ion channel drug discovery. Adjacent to MaxWell's electrophysiology franchise with overlapping pharma safety-pharmacology customers, but focused on single-cell/manual patch rather than network-level MEA recording.

Broad incumbents

  • Molecular Devices: Large-scale life-science instrumentation provider (part of Danaher) offering patch-clamp, MEA, and high-content screening platforms. Addresses similar neuroscience and drug-discovery customers but as part of a much broader portfolio including microplate readers and imaging systems.
  • Bruker (Cellular Analysis / Nanostring-era acquisition portfolio): Large analytical instrument manufacturer with presence in neuroscience and cellular analysis. Comparable end customers in pharma and academic neuroscience, but MaxWell's HD-MEA is a niche offering within Bruker's broader microscopy and proteomics portfolio.

Others

  • Charles River Laboratories: Major CRO offering electrophysiology and safety-pharmacology services, including iPSC-derived neuron screening. Serves as both a potential customer (uses HD-MEA platforms in service offerings) and a competitive threat for outsourced preclinical neuroscience work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

MaxWell Biosystems social profiles

Digital presence

MaxWell Biosystems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MaxWell Biosystems leadership team

Management profile

Number of profiles

Profiles14 records

MaxWell Biosystems subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

MaxWell Biosystems funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MaxWell Biosystems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MaxWell Biosystems

What does MaxWell Biosystems do?

MaxWell Biosystems manufactures and sells High-Density Microelectrode Array (HD-MEA) instruments, chips, and software that record and stimulate electrophysiological activity from neurons at single-cell and subcellular resolution. Its flagship products are the MaxOne single-well platform and the MaxTwo multi-well platform, paired with the MaxLab Live software suite, and are used by neuroscience and preclinical drug discovery laboratories worldwide.

Is MaxWell Biosystems a public or private company?

MaxWell Biosystems is a private company. It is classified as venture growth investor backed and is currently operating.

When was MaxWell Biosystems founded?

MaxWell Biosystems was founded in 2016. It employs 11 to 50 people.

Where is MaxWell Biosystems based?

MaxWell Biosystems is headquartered in Zurich, Switzerland, in the Europe region.

How does MaxWell Biosystems make money?

Four revenue lines are on record. HD-MEA Hardware Systems are the primary driver. The others are MEA Chips and Consumables, software Licenses and Support and technical Support and Training.

Who are MaxWell Biosystems's main competitors?

Direct peers on record are MaxWell Biosystems MCS (Multi Channel Systems), Axion Biosystems and CytoView (formerly MED64, by Alpha MED Scientific). Emerging players are Nanion Technologies, Blackrock Microsystems, Imec and Sophion Bioscience. Broad incumbents are Molecular Devices and Bruker (Cellular Analysis / Nanostring-era acquisition portfolio). Charles River Laboratories is listed as an others.

Does MaxWell Biosystems have an API?

No public API is recorded for MaxWell Biosystems.

What industry is MaxWell Biosystems in?

MaxWell Biosystems's product category is Electrophysiology Instrumentation. Its primary akta.pro industry code is HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS), with a secondary code of HDAHAAAG, Sensors, MEMS & Imaging ICs. Its NAICS code is 334515 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireRice Biotech Launch Pad to Sponsor 2nd Edition of the BioElectronic Therapeutics (BETx) Event hosted by the Rice Global Paris Center in JuneThe Rice Biotech Launch Pad will sponsor the second BioElectronic Therapeutics (BETx) workshop in Paris on June 10-12, hosted by the Rice Global Paris Center. The event will feature over 20 speakers from industry, academia, and investment, with panels on bioelectronic technologies and commercialization. Applications are being accepted for attendance.The Mercury NewsUC Santa Cruz study shows developing brains have inherent structureUC Santa Cruz researchers published a study in Nature Neuroscience showing that developing brain tissue exhibits spontaneous electrical activity and structure without any sensory input, challenging the long-held "tabula rasa" (blank slate) theory of brain development. The researchers used lab-grown brain organoids and high-resolution microelectrode arrays from MaxWell Biosystems to demonstrate that neurons fire in preconfigured sequences established during neurogenesis, suggesting brains are "prewired" with an innate architecture. The findings may improve understanding of neurodevelopmental disorders such as Parkinson’s and autism, and have implications for biocomputing research.startupticker.chLoan guarantees for five startupsSwitzerland's Technology Fund has added five new startups to its portfolio of loan guarantees for climate-tech companies, including Aliunid, MaxWell Biosystems, KITRO, FGen and Sport Components. The fund has issued CHF 188 million to 110 companies, with 54% reducing carbon emissions directly, and has CHF 350 million available.